Introduction {#s1}
============

The determination of the oligomeric state of transport proteins is an important step in resolving their mechanism. The oligomeric state can be assessed by different sizing techniques, by binding and transport studies or by biophysical and structural methods. However, these studies are often marred with controversy. Since these experiments deal with membrane proteins, they are technically challenging, as many complicating factors often lead to incorrect assignments of the oligomeric state.

In this review, we discuss studies related to the oligomeric state of the mitochondrial ADP/ATP carrier, also called the adenine nucleotide translocator or translocase, which belongs to the mitochondrial carrier family (SLC25) \[[@BST-48-1419C1]\]. Mitochondrial carriers form the largest solute carrier family in humans and are involved in the transport of amino acids, carboxylic acids, fatty acids, cofactors, inorganic ions and nucleotides across the mitochondrial inner membrane \[[@BST-48-1419C1]\]. Their transport activities are central to many cellular processes, such as the oxidation of degradation products of fats and sugars, the synthesis of iron sulfur clusters and haem, and the degradation, synthesis and interconversion of amino acids, as well as mitochondrial macromolecular synthesis, ion homeostasis, heat production, mitochondrial dynamics, signalling, cellular differentiation, development and cell death \[[@BST-48-1419C1],[@BST-48-1419C5]\]. Disease variants of mitochondrial carriers lead to a diverse range of neuromuscular, metabolic and developmental diseases \[[@BST-48-1419C3],[@BST-48-1419C4]\].

The mitochondrial ADP/ATP carrier is the best-studied member of the SLC25 family. It was one of the first transporters to be characterised in detail, because of its natural abundance \[[@BST-48-1419C6]\]. Based on a careful analysis of the binding properties of two specific inhibitors, carboxyatractyloside and bongkrekic acid, an alternating access mechanism was proposed, also called the single binding centre gated pore mechanism \[[@BST-48-1419C6]\]. When the first amino acid sequences were determined \[[@BST-48-1419C9]\], it became clear that mitochondrial carriers consist of three homologous repeats \[[@BST-48-1419C12]\] and have six transmembrane α-helices \[[@BST-48-1419C13]\]. Back then, it was thought that a six-helical membrane protein might be too small for transporting large substrates, such as ATP and palmitoyl carnitine. A dimer would be more compatible with the 12 α-helical topologies generally observed at the time and it was suggested that dimerisation might be a key generic property of transporters \[[@BST-48-1419C14]\]. The results of a large number of biophysical and biochemical experiments subsequently seemed to support the notion that mitochondrial carriers exist and function as dimers (reviewed in \[[@BST-48-1419C15]\]). However, when the first structural information became available, it became clear that the mitochondrial ADP/ATP carrier is a monomer with a three-fold pseudo-symmetrical structure and a translocation pathway through the centre, indicating that it could work as a monomer as well \[[@BST-48-1419C16]\]. Subsequent atomic structures have supported a monomeric fold of the mitochondrial ADP/ATP carrier \[[@BST-48-1419C1],[@BST-48-1419C8],[@BST-48-1419C17]\]. One structural study suggested that dimerisation might be mediated via cardiolipin interactions, based upon analysis of the protein--protein interactions that form the crystal \[[@BST-48-1419C20]\]. However, these interactions are weak and would provide no specificity of recognition in the presence of 50 structurally related but functionally different mitochondrial carriers present in the inner membrane. Since crystallization conditions are designed to favour protein--protein interactions, analysis of crystal packing will potentially reveal non-physiological oligomers \[[@BST-48-1419C21]\]. A careful re-examination of all packing arrangements has shown that there is no conserved dimerisation interface, indicating that the carriers are structural monomers \[[@BST-48-1419C17]\]. The only verified exception in the SLC25 family is the mitochondrial aspartate/glutamate carrier, which forms a structural dimer due to its unusual architecture \[[@BST-48-1419C22]\]. In addition to a carrier domain, which is similar in structure to the mitochondrial ADP/ATP carrier, it has an N-terminal calcium regulatory domain and C-terminal amphipathic helix. Aspartate/glutamate carriers dimerise via their regulatory domains, as five of the eight EF-hand motifs have evolved away from their canonical calcium-binding function to form an extensive dimerisation interface. In contrast, the two carrier domains do not interact and are likely to transport as separate units \[[@BST-48-1419C22]\]. The mitochondrial ATP-Mg/phosphate carrier also has a calcium regulatory domain, but it has a different architecture and is a structural monomer \[[@BST-48-1419C23]\].

So, why did the earlier studies conclude that mitochondrial carriers are dimers? We have extensively reviewed these issues in 2010 \[[@BST-48-1419C15]\], but it is worthwhile highlighting some of the key points, as the same technical mistakes are still made. First of all, it is extremely important to use a good quality starting material for studies of the oligomeric state. Mitochondrial carriers are highly dynamic membrane proteins with very few polar interactions stabilising their structures, which can cause major issues with almost every aspect of this analysis. There are many potential issues with their expression, targeting, insertion and folding, when they are produced through heterologous expression. In the Gram-negative bacterium *Escherichia coli* they end up in inclusion bodies in a misfolded and aggregated state \[[@BST-48-1419C26]\], whereas in the Gram-positive bacterium *Lactococcus lactis* they are targeted to the cytoplasmic membrane \[[@BST-48-1419C27]\], but a fraction might be misfolded \[[@BST-48-1419C28]\]. Mitochondrial carriers expressed in the inner mitochondrial membrane of yeast or mammalian cells, using the endogenous synthesis, targeting, insertion and folding pathways, are the best starting point. Yeast is preferred because cultures can be scaled up easily, a requirement for studying organellar membrane proteins that are comparatively in low abundance \[[@BST-48-1419C31]\].

Oligomeric state of mitochondrial carriers in detergent {#s2}
=======================================================

Purified carrier in detergent is a good starting point, as its oligomeric state can be determined away from contaminants. Detergents are required to solubilise the carrier from the lipidic membrane and to take it through several purification steps to obtain a pure sample. The choice of detergent is crucial, as harsh detergents can intercalate and unfold the protein, leading to structural instability and aggregation, an artificial state. It is also possible that detergents can separate oligomers into protomers, misrepresenting its true nature. However, if a suitably mild detergent is chosen, its atomic structure and oligomeric state are preserved, as observed for many other transporters, such as the dimeric Na^+^/H^+^ antiporter \[[@BST-48-1419C34]\], Na^+^/betaine symporter BetP \[[@BST-48-1419C35]\], the band 3 protein \[[@BST-48-1419C36]\] and the trimeric sodium/aspartate symporter Glt~Ph~ \[[@BST-48-1419C37]\]. Analysis of the oligomerization interfaces of membrane proteins shows features shared with those of soluble proteins: the interfaces tend to be large and tightly packed, involving a multitude of residues \[[@BST-48-1419C38]\].

When any sizing method is used, it is extremely important to account for the contribution of the detergent/lipid micelle associated with the membrane protein. As mitochondrial carriers are relatively small, the contribution of the micelle to the total mass can be relatively large. In size exclusion chromatography, the total mass of the yeast ADP/ATP carrier can be as much as 115 kDa in dodecylmaltoside or 134 kDa in tridecylmaltoside. However, when the detergent/protein weight ratios are determined, giving 2.4 and 3.0, respectively, the carriers are clearly monomeric (33.8 and 33.5 kDa) \[[@BST-48-1419C39],[@BST-48-1419C40]\].

In blue native gel electrophoresis, the molecular mass of mitochondrial carriers is systematically overestimated, because they run as a protein/detergent/lipid/Coomassie complex rather than a protein/Coomassie complex, as often assumed \[[@BST-48-1419C41]\]. The size changes with different detergent and lipid content of the associated micelle, showing that they are key factors. By complete coincidence, the apparent mass of the protein in dodecylmaltoside comes out to be ∼66 kDa, which is roughly twice the theoretical molecular mass, but when contributions of detergent, lipid and Coomassie are taken into account, it is a monomer \[[@BST-48-1419C41]\]. In the case of the mitochondrial pyruvate carrier (SLC54) in digitonin, the molecular mass was 150 kDa in blue native gel electrophoresis \[[@BST-48-1419C42]\], but in reality, it is 31 kDa \[[@BST-48-1419C43]\]. Thus, this method is not a reliable sizing technique for small membrane proteins \[[@BST-48-1419C41]\].

Another important technical issue has been that protein assays can be adversely affected by the presence of detergents and lipids. When a protein is purified in Triton X-100, the modified Lowry assay overestimates the protein content considerably \[[@BST-48-1419C44]\], which has affected the outcome of binding studies with inhibitors, resulting in inhibitor/carrier stoichiometries of 1 : 2 \[[@BST-48-1419C45]\]. It is better to use the bicinchoninic acid assay, or better still, amino acid analysis, which provides an accurate measure of protein concentration, irrespective of the detergent and lipid content of the sample. We now know that the inhibitor/carrier stoichiometries are 1 : 1 from calorimetry measurements \[[@BST-48-1419C48]\] and structural analysis \[[@BST-48-1419C17]\]. The quantification of protein has also affected the interpretation of analytical ultracentrifugation data due to the overestimation of the protein contribution \[[@BST-48-1419C49],[@BST-48-1419C50]\], but subsequent studies have confirmed that the carriers are monomeric using this technique \[[@BST-48-1419C39],[@BST-48-1419C51]\].

Small-angle neutron scattering (SANS) offers the potential for determining the oligomeric state of membrane proteins in detergent solution, since contrast matching by deuterium exchange can allow the contributions from lipid and detergent to be removed from the scattering data \[[@BST-48-1419C52]\]. However, bovine AAC1 in LAPAO was estimated to be 53, 56 or 61 kDa \[[@BST-48-1419C53]\] and more recently 44 kDa \[[@BST-48-1419C51]\], reflecting the difficulties with completely masking the contribution of lipid/detergent micelles by deuterium exchange when in large excess, leading to an overestimation of the protein mass.

The combination of size exclusion chromatography with multi-angle laser light scattering (SEC-MALLS) is a reliable method for determining the mass of membrane protein in a micelle, which can accurately account for the contributions from detergent and lipid \[[@BST-48-1419C54]\]. It has been successfully applied to several mitochondrial transporters \[[@BST-48-1419C22],[@BST-48-1419C43]\], giving the correct mass, but it is essential that they are separated fully from contaminants and free detergent micelles \[[@BST-48-1419C54]\].

To analyse whether membrane proteins form a complex in detergents, one can also apply a differential tagging strategy, where tagged and untagged versions of the protein are co-expressed in the membrane and purified by affinity chromatography \[[@BST-48-1419C55]\]. If they were to form a complex, the untagged proteins should co-purify with the tagged protein upon elution. For the yeast ADP/ATP carrier, all untagged carriers were found in the flow through, whereas all tagged carriers were found in the elution fraction, showing no state-dependent association even in the mildest detergents \[[@BST-48-1419C55]\]. In our opinion there has never been a valid observation of a dimer of the mitochondrial ADP/ATP carrier in detergent, when all technical issues are taken into account.

The mitochondrial ADP/ATP carrier functions as a monomer {#s3}
========================================================

A key question that needed to be resolved is whether the mitochondrial ADP/ATP carrier requires dimerisation for function. One observation that has been held in favour is the autosomal dominant inheritance of progressive external ophthalmoplegia, which is caused by missense mutations in the gene coding for the human ADP/ATP carrier 1, also called SLC25A4 or ANT1 \[[@BST-48-1419C56]\]. However, dominant inheritance *per se* does not provide proof for dimer formation, as there are many other genetic mechanisms leading to dominant inheritance, such as (i) increased gene dosage; (ii) ectopic or temporally altered mRNA expression; (iii) increased or constitutive protein activity; (iv) altered structural proteins; (v) toxic protein alterations; (vi) new protein function; and (vii) reduced gene dosage, expression or protein activity, also called haploinsufficiency \[[@BST-48-1419C57]\]. It has been estimated that the mitochondrial ADP/ATP carriers in the human body need to transport the equivalent of ∼65 kg of ADP and ATP across the inner mitochondrial membrane every day to fuel our cellular processes \[[@BST-48-1419C58],[@BST-48-1419C59]\]. Given this enormous flux, it is likely that any failure of a fraction of the carrier population would lead to issues with mitochondrial function and energy provision, and eventually to disease, pointing to haploinsufficiency as a plausible mechanism. However, genetics alone is not sufficient to resolve these issues conclusively, as it needs to be investigated by studying negative dominance on protein function directly. In yeast, no negative dominance was observed in transport, demonstrating that the carriers function independently from each other in the mitochondrial inner membrane \[[@BST-48-1419C60]\]. Furthermore, when the ADP/ATP carrier is tagged with different lengths of poly-histidine tags, the expression levels decreased with increasing tag length. The growth rates of the strains expressing these modified carriers on glycerol, a nonfermentable carbon source, decreased with decreasing expression level, demonstrating haploinsufficiency (unpublished data, Marilyn Harding).

However, the most compelling argument for the carrier being active as a monomer is that it has all of the functional features required for transport: a single central substrate-binding site and two gates with salt bridge networks that provide access to one or the other side of the membrane in an alternating way \[[@BST-48-1419C1],[@BST-48-1419C8],[@BST-48-1419C17],[@BST-48-1419C18],[@BST-48-1419C61]\].

The mitochondrial ADP/ATP carrier is a monomer in the membrane {#s4}
==============================================================

The one issue that has not been resolved is the oligomeric state of the mitochondrial ADP/ATP carrier in the inner membrane. There are plenty of cases where membrane proteins or protein complexes function as monomers, but form dimers or oligomers in the membrane, such as the mitochondrial ATP synthase (dimer) \[[@BST-48-1419C65]\], the glutamate transporter (trimer) \[[@BST-48-1419C66]\] and aquaporin (tetramer) \[[@BST-48-1419C67]\]. The mitochondrial inner membrane is one of the most densely packed of all and the mitochondrial ADP/ATP carrier is the most abundant protein therein. Even if the carrier functions as a monomer, it is still possible that it is present in some close-packing arrangement. There are very few studies that have addressed this particular possibility.

In one study, the bovine ADP/ATP carrier was reconstituted into liposomes and its diameter was determined by freeze-fracture electron microscopy, giving an average of ∼75 Å \[[@BST-48-1419C68]\]. No correction for the thickness of the stain layer was carried out, which can be as much as ∼17 Å \[[@BST-48-1419C69]\]. The matrix side of the bovine ADP/ATP carrier has a diameter of ∼42 Å and is the only part that protrudes significantly from the membrane \[[@BST-48-1419C64],[@BST-48-1419C70]\]. Thus, the size of the observed particles, corrected for the contribution of the stain layer, is only compatible with a monomer. The particles are not dimeric, otherwise, they would have had a pronounced elongated appearance, which is not evident in the micrographs, nor do they form ordered clusters. In another study, high-density membranes with reconstituted yeast ADP/ATP carrier did not show any systematic dimeric arrangements, when scanned with atomic force microscopy \[[@BST-48-1419C70]\]. Thus, these studies show that the carriers do not form preferred dimeric interactions in membranes after reconstitution, but they do not address what happens in the mitochondrial membrane itself.

Recently, new claims for a dimeric state of the bovine ADP/ATP carrier have emerged based on native mass spectrometry of injected mitochondrial membranes \[[@BST-48-1419C71]\], although it should be noted that the method has already attracted criticism for the failure to preserve the quaternary structure and oligomeric state of mitochondrial complexes \[[@BST-48-1419C72]\]. Native mass spectrometry is an established technique for the analysis of the oligomeric state and the chemical composition of tightly bound molecules to membrane proteins, purified in detergents \[[@BST-48-1419C73]\]. These native mass spectra are complex because of the binding of lipid and detergent molecules in variable amounts, as well as ligands and contaminants. In the new approach, membrane vesicles are injected directly, giving the combined mass spectra of hundreds of different membrane proteins and membrane-associated proteins in variable relative abundance and charge. The interpretation of these spectra is extremely complex, complicated further by the association of different molecules and by post-translation modifications.

In the study in question, masses were assigned to both monomeric and dimeric states of the mitochondrial ADP/ATP carrier in isolated membranes from bovine heart, giving 33 195 and 66 387 Da, respectively \[[@BST-48-1419C71]\], with the dimer being the most abundant form. The molecular mass of the bovine ADP/ATP carrier has been determined independently twice before. The first-ever amino acid sequence for the SLC25 family was determined by peptide sequencing of proteolytic fragments of the purified native bovine carrier. The study concluded that the mature protein lacks the N-terminal Met and has an acetylated Ser1 and a trimethylated Lys51 \[[@BST-48-1419C9],[@BST-48-1419C76],[@BST-48-1419C77]\], giving a total mass of 32 921 Da. Residue numbering consequently differs from the protein encoded by the gene, but is consistent with the Protein Data Bank entries of the bovine structure (1OKC, 2C3E) \[[@BST-48-1419C19]\]. The first two modifications are common in mitochondrial carriers, e.g. the uncoupling protein \[[@BST-48-1419C10],[@BST-48-1419C48]\], and the third has been observed in other mitochondrial proteins, e.g. the c-ring of mitochondrial ATP synthase \[[@BST-48-1419C78]\], for which a specific methyltransferase has been identified \[[@BST-48-1419C79]\]. The second independent study carried out a total molecular mass determination of purified bovine carrier using mass spectrometry, and concluded that it was 32 925.3 ± 3.2 Da \[[@BST-48-1419C80]\], which agrees with the mass of the modified protein determined from the first study. Thus, there is a clear discrepancy between the mass observed in native mass spectrometry \[[@BST-48-1419C71]\] and the one determined by protein sequencing \[[@BST-48-1419C9]\] and mass spectrometry \[[@BST-48-1419C80]\], which is not accounted for by experimental error. In a subsequent study, this discrepancy was attributed to a large number of post-translational modifications \[[@BST-48-1419C81]\]. In addition to the ones mentioned above, they observed *O*-acetylation of another four residues, Thr23, Tyr50, Tyr111 and Tyr190, *N*-succinylation of Lys22 and Lys271, and *N*-trimethylation of Lys9. They note that there might be other modifications, but only the ones with high confidence are reported. This extensively modified carrier must be the predominant species in the membrane, as no other was discernable in the native mass spectrometry data. Since high-resolution structures of the bovine ADP/ATP carrier have been solved, we checked whether there is any evidence for the additional post-translational modifications in the electron density maps \[[@BST-48-1419C19],[@BST-48-1419C20]\]. In any crystal structure, regions of a protein can be disordered and hence show weak or no electron density, which cannot be reliably modelled. To avoid these issues, we have focussed on the structure solved at the highest resolution (2.2 Å, PDB code: 1OKC), and on residues that lie in well-ordered regions, with low B-factors, where the electron density map shows clear density for backbone carbonyl oxygens and water molecules. A careful inspection of these sites shows that there are no additional unexplained electron densities near the side chains of these residues, and hence no evidence for their post-translational modification ([Figure 1](#BST-48-1419F1){ref-type="fig"}). To exclude the remote possibility that the bulk-solvent model used in crystallographic refinement and map calculation might have flattened the electron density near the side chains, we have calculated a polder OMIT map for each residue \[[@BST-48-1419C82]\]. These maps confirm that there is no crystallographic support for the proposed post-translational modifications. Thus, the data from three different techniques are consistent with each other with respect to the mass and level of modification \[[@BST-48-1419C9],[@BST-48-1419C76],[@BST-48-1419C80]\], but not with those observed by native mass spectrometry \[[@BST-48-1419C71],[@BST-48-1419C81]\].

![Electron density maps do not support the claimed post-translational modifications of the bovine ADP/ATP carrier.\
The 2mFo − DFc electron density maps around (**A**) Lys 9, (**B**) Thr23, (**C**) Tyr50, (**D**) Tyr111, (**E**) Tyr190 and (**F**) Lys271, shown as a grey mesh and contoured at the root mean square electron density (1σ), using structure factors and atomic co-ordinates from the Protein Data Bank (PDB code: 1OKC). The carrier is shown in cartoon representation with side chains as sticks, coloured by domain (domain 1, blue; domain 2, yellow; domain 3, red), whereas the residues that are claimed to be modified are shown in green. Cardiolipins are shown in dark grey and carboxyatractyloside in teal. Water molecules are shown as red spheres. Hydrogen bonds are indicated by black dashed lines, with distances indicated (Å). The side-chain of Asn73, which interacts with Thr23, has been flipped to maximise its hydrogen-bonding potential.](BST-48-1419-g0001){#BST-48-1419F1}

Next, we inspected the sites of the proposed modifications in the context of the structure and mechanism of the ADP/ATP carrier. In the structure, residues Thr23, Tyr50 and Lys271 are involved in key interactions that stabilise the domain structures, and their modification would lead to disruption and destabilisation of the carrier ([Figure 1](#BST-48-1419F1){ref-type="fig"}). Tyr50, which is bonded to two other residues, is in a structural environment that could not possibly accommodate an acetylation modification. Thr23 is inaccessible for modification in the cytoplasmic-state, where the side-chain is packed between a neighbouring transmembrane α-helix and the lipid bilayer, and in the matrix-state, where it is buried in the bilayer \[[@BST-48-1419C18],[@BST-48-1419C19]\]. Therefore, Thr23 and Tyr50 could only become modified when the protein is unfolded.

To justify the assignment of the 33 195 Da mass to the ADP/ATP carrier, control experiments were performed in which two specific inhibitors were added to the membrane prior to analysis by native mass spectrometry \[[@BST-48-1419C81]\]. The experimental conditions are not described, and a concentration dependency of binding was not determined, and thus it is impossible to verify whether the observed low-level binding is specific or non-specific. However, we can confirm that *N*-succinylation of Lys22 would interfere with the binding of these inhibitors, as the modification would be located in their binding pockets ([Figure 2](#BST-48-1419F2){ref-type="fig"}). The amine group of Lys22 binds via an ordered water to the carboxyl group of carboxyatractyloside in the cytoplasmic state of the bovine carrier \[[@BST-48-1419C17],[@BST-48-1419C19]\] ([Figure 2C](#BST-48-1419F2){ref-type="fig"}). In the matrix state structure of the ADP/ATP carrier of *Thermothelomyces thermophila*, Lys30, the equivalent residue of Lys22, binds directly to a carboxyl group of bongkrekic acid \[[@BST-48-1419C18]\] ([Figure 2D](#BST-48-1419F2){ref-type="fig"}). So, in both cases, the proposed modification would abolish these interactions. The positively charged Lys22 is also a key residue in the binding of the negatively charged substrates ADP and ATP ([Figure 3](#BST-48-1419F3){ref-type="fig"}) \[[@BST-48-1419C8],[@BST-48-1419C61],[@BST-48-1419C83]\]. *N*-succinylation of Lys22 would (i) introduce a large group in the binding pocket of the substrates and inhibitors, (ii) abolish a positive charge providing key ionic interactions with their negatively charged functional groups and (iii) introduce a negatively charged modification where the negatively charged compounds are supposed to bind, creating electrostatic repulsion. It is also possible that the negatively charged succinyl modification could form ionic interactions with either Arg79 or Arg279, removing two of the three positive charges from the site, which are crucial for the binding of the substrates. Thus, the highly modified carrier could not be in a folded and functional state, capable of binding inhibitors or substrates.

![Structures of mitochondrial ADP/ATP carriers inhibited by specific inhibitors.\
(**A**) Lateral view of the structure of the bovine ADP/ATP carrier (PDB code: 1OKC) trapped in the cytoplasmic-state by the inhibitor carboxyatractyloside (CATR), which was refined with the correct stereo-isoform of CATR \[[@BST-48-1419C107]\]. (**B**) Lateral view of the structure of the ADP/ATP carrier of *Thermothelomyces thermophila* (PDB code: 6GCI) trapped in the matrix-state by the inhibitor bongkrekic acid (BKA). The carriers are shown in cartoon representation coloured by domain (blue, domain 1; yellow, domain 2; red, domain 3) and with the gate elements on the even-numbered transmembrane α-helices in grey. Details of protein-inhibitor interactions are shown in (**C**) for CATR and (**D**) for BKA. The lysine residue that is claimed to be succinylated is indicated by a red label. The inhibitors are shown in teal for CATR and in orange for BKA, whereas cardiolipin molecules are shown in grey. Polar interactions between protein and inhibitors are indicated by green dotted lines. IM mitochondrial inner membrane.](BST-48-1419-g0002){#BST-48-1419F2}

![Succinylation of Lys22 would interfere with substrate binding.\
(**A**) Residues of the proposed substrate-binding site, shown in green, in the cytoplasmic state of the bovine ADP/ATP carrier (PDB:1OKC) \[[@BST-48-1419C19]\]. The three positively charged residues (Lys22, Arg79, Arg279) are predicted to form salt bridge interactions with the negatively charged phosphate groups of the substrates ADP and ATP. Gly182, Ile183, Tyr186 and Ser227 form the adenine binding pocket. ADP is shown in stick and surface representation at the van der Waals radii of the atoms, for comparison. (**B**) The proposed post-translational succinylation of Lys22 (Suc-Lys22), here represented by the three possible conformers, would sterically hinder substrate binding and significantly alter the electrostatic potential of the binding site by removing a positive charge and by introducing a negative charge. Moreover, the succinyl modification could form an ionic interaction with either Arg79 or Arg279, removing two of the three positive charges from the site, compromising the binding of the negatively charged ADP^3−^ or ATP^4−^.](BST-48-1419-g0003){#BST-48-1419F3}

A large number of independent studies have reported the importance of three tightly bound cardiolipin molecules in the structure and transport mechanism of mitochondrial carriers, including phosphorous NMR \[[@BST-48-1419C86]\], crystallographic analyses \[[@BST-48-1419C17]\], lipid analysis \[[@BST-48-1419C39],[@BST-48-1419C40],[@BST-48-1419C48],[@BST-48-1419C87]\], disease models \[[@BST-48-1419C88]\], thermostability measurements \[[@BST-48-1419C91]\], transport assays \[[@BST-48-1419C83],[@BST-48-1419C92],[@BST-48-1419C93]\] and coarse grain and molecular dynamics simulations \[[@BST-48-1419C94]\]. The measured mass of 33 195 Da, assigned to the bovine ADP/ATP carrier by native mass spectrometry, does not account for the binding of three cardiolipin molecules, otherwise, it would have been 37 271 Da. Moreover, the spectrum does not show the typical fine-splitting of the native mass peak due to bound cardiolipin or other lipid molecules having acyl chains of differing length and saturation. To explain the missing cardiolipin molecules, it was incorrectly asserted that the cardiolipins observed in the crystal structures were present because cardiolipin was added during purification and crystallisation trials \[[@BST-48-1419C81]\]. Actually, in most cases, the carrier was isolated directly from the mitochondrial inner membrane in detergent solutions without cardiolipin addition \[[@BST-48-1419C17],[@BST-48-1419C19],[@BST-48-1419C20]\]. Cardiolipin molecules are so tightly bound that extensive washing with detergents does not remove them \[[@BST-48-1419C39],[@BST-48-1419C48]\]. Cardiolipin binding occurs at three specific sites in the mitochondrial ADP/ATP carrier, which have special properties ([Figure 4A](#BST-48-1419F4){ref-type="fig"}). The two negatively charged phosphate moieties of cardiolipin are bound between the N-terminus of the even-numbered helix of one domain and the N-terminus of the matrix helix of the proximal domain. They are bonded by hydrogen bonds \[[@BST-48-1419C19],[@BST-48-1419C20]\] and by electrostatic interactions with the positive helix dipole \[[@BST-48-1419C17],[@BST-48-1419C18],[@BST-48-1419C64]\], explaining their high-affinity binding ([Figure 4B](#BST-48-1419F4){ref-type="fig"}). For these reasons, the loop to helix transitions have highly conserved \[YF\]xG and \[YWF\]\[RK\]G motifs, where the glycine residues function as helix breakers \[[@BST-48-1419C18],[@BST-48-1419C64],[@BST-48-1419C97]\]. The bound cardiolipin molecules are important for the stability and function of the carrier, as they link two adjacent domains together when the carrier cycles between the matrix and cytoplasmic state.

![Three cardiolipin molecules are tightly bound to the mitochondrial ADP/ATP carrier.\
(**A**) Side and matrix view of bovine adenine nucleotide translocase (2CE3), showing three tightly bound cardiolipin molecules. Domains 1, 2 and 3 are shown in blue, yellow and red, respectively, and the gate elements in grey. The cardiolipin molecules are shown in cyan and their acyl chains have only been partially modelled. (**B**) The negatively charged cardiolipin molecules are tightly bound by electrostatic interactions with the helix dipoles, which have a formal positive charge (δ+), and by hydrogen bonds between the phosphate moieties and amide groups (blue spheres) of the even-numbered transmembrane helices, here H4, and matrix helices, here h56. The cardiolipin binding sites are highly conserved and the consensus sequence for the even-numbered helices (left) and matrix helices (right) is shown. The dashed line represents the inter-domain interface. IS, intermembrane space; IM inner membrane; MM mitochondrial matrix; CDL cardiolipin molecule.](BST-48-1419-g0004){#BST-48-1419F4}

Since the carrier is relatively small and embedded in a lipid bilayer, and has short loops, most of the protein is not accessible for enzyme-mediated post-translational modifications. However, reactive metabolites, such as acetyl-CoA and succinyl-CoA, can potentially directly react with amino acid side chains \[[@BST-48-1419C98]\], which could occur more readily in the mitochondrial matrix, which has an alkaline pH and relatively high concentrations of these compounds \[[@BST-48-1419C99]\]. Non-enzymatic acetylation and succinylation of lysines in mitochondrial proteins has been reported, but they occur with low stoichiometry \[[@BST-48-1419C102],[@BST-48-1419C103]\]. The acetylation of threonine and tyrosine residues has been described, but also appears to be rare \[[@BST-48-1419C104],[@BST-48-1419C105]\]. If real, the modified residues would be inaccessible to enzymes and there is no known non-enzymatic mechanism for removal of the modifications, so this cannot be regulatory.

So, how could the highly modified carrier become the dominant form in these studies, whereas it is not observed at all in other analyses? Significantly, prior to mass spectrometry, the membranes were sonicated in 0.5 M of ammonium acetate buffer to remove bound ions and to facilitate extraction of proteins from the membrane \[[@BST-48-1419C106]\]. The sonication procedures and the high voltages used for electrospray ionisation will have deposited a lot of energy into the sample, which may explain the unusually high level of modifications. Consistent with this, the experimental procedures have also led to the disruption of the mitochondrial ATP synthase and complex III dimers, to the removal of a large number of subunits from complex I and III, and to the complete removal of lipids, normally associated with membrane proteins \[[@BST-48-1419C72]\]. The disrupted interaction surfaces of the mitochondrial complexes are many orders of magnitude larger than those of any hypothetical carrier dimer, which would only contain a few amino acids. The protein, assigned to the ADP/ATP carrier by native mass spectrometry, seems to lack all of the known properties of the native one in the inner membrane of mitochondria, i.e. molecular mass, level of modification and cardiolipin binding. If we assume the assignment is correct, these treatments have led to structural destabilisation, hyper-modification and delipidation of the mitochondrial ADP/ATP carrier, which could lead to non-specific aggregation. Under these conditions, any assessment of the oligomeric state becomes pointless, as the native state and function of these highly labile proteins have not been preserved by the method of analysis.

Simulations addressing the oligomeric state of the mitochondrial ADP/ATP carrier {#s5}
================================================================================

Coarse grain simulations have been used to study the behaviour of an ensemble of mitochondrial ADP/ATP carriers in simulated membranes \[[@BST-48-1419C71],[@BST-48-1419C95]\]. For these analyses, the carboxyatractyloside-inhibited state of the ADP/ATP carrier was used, after the removal of the inhibitor. The inhibitor locks the carrier in an abortive state, which is not part of the transport cycle \[[@BST-48-1419C6]\]. Comparisons to the bongkrekic acid-inhibited state have shown that there are some structural perturbations induced by inhibitor binding consistent with the state being abortive \[[@BST-48-1419C18]\]. Thus, the question is whether it was a good starting point for this type of analysis. In reality, the carriers cycle continuously between a cytoplasmic and matrix conformation, each of them being in a different state, and this currently cannot be modelled accurately. Nevertheless, in these simulations, the carriers form dimers, trimers, tetramers and higher-order aggregates. Notably, they form predominantly if cardiolipin was present in the inner leaflet of the membrane \[[@BST-48-1419C71]\]. However, and most importantly, the carriers do not associate in a consistent way and do not have a conserved dimerisation interface. Associations occur on all sides of the carriers without specificity, roughly following the three-fold pseudo-symmetrical shape of the carrier. Rather than forming specific dimers, the carriers are arranged in closely-packed clusters without conserved interactions.

New insight from structural analysis {#s6}
====================================

In the functional mitochondrion, mitochondrial carriers cycle back and forth between the cytoplasmic and matrix state, both of which have been characterised structurally for the ADP/ATP carrier ([Figure 2A,B](#BST-48-1419F2){ref-type="fig"}) \[[@BST-48-1419C17]\]. The conformational changes involve six elements, which move concomitantly \[[@BST-48-1419C8],[@BST-48-1419C18]\]. There are three core elements, which consist of the odd-numbered helices, the matrix helices and one-third of the even-numbered helices (primary colours, [Figure 2A,B](#BST-48-1419F2){ref-type="fig"}) plus three gate elements, which are the C-terminal ends of the even-numbered helices in each domain (grey colours, [Figure 2A,B](#BST-48-1419F2){ref-type="fig"}) \[[@BST-48-1419C8],[@BST-48-1419C18]\]. During the transition from the cytoplasmic to the matrix state, the core elements of each domain rock outwards, opening the matrix side of the carrier, whereas simultaneously the gate elements rotate inwards, closing the cytoplasmic side of the carrier ([Figure 2A,B](#BST-48-1419F2){ref-type="fig"}). The transition between the matrix and cytoplasmic state involves the movement of the same elements, but in reverse \[[@BST-48-1419C8],[@BST-48-1419C18]\]. The conformational changes lead to profound changes in shape that are totally incompatible with a stable dimerisation interface ([Figure 2A,B](#BST-48-1419F2){ref-type="fig"}) \[[@BST-48-1419C63]\]. Small movements in the substrate-binding site \[[@BST-48-1419C61]\] translate to large movements on the periphery of the carrier, some as much as 13 Å \[[@BST-48-1419C18]\]. The inner membrane of a fully functional mitochondrion contains 50 different mitochondrial carriers, each in a different conformational state in the transport cycle at any one time. The carriers cycle between these states approximately a thousand times per second. With this in mind, and all the other arguments presented in this review, it is simply not possible that they form stable structural dimers during transport of their substrates.

Perspectives
============

-   **Importance of the field:** The mitochondrial ADP/ATP carrier performs one of the most important transport steps in the human body, transporting the spent fuel ADP into the mitochondrion and the synthesised fuel ATP out to energise processes in the cell.

-   **Current thinking:** Originally it was thought that they were dimers, but all of the sequence, structural, biophysical and functional data now show that the mitochondrial ADP/ATP carrier exists and functions as a monomer.

-   **Future directions:** Many structural aspects of the transport mechanism still need to be resolved to determine how mitochondrial ADP/ATP carriers achieve high transport rates of adenine nucleotides in the densely packed inner membrane of mitochondria.
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SANS

:   small-angle neutron scattering

SEC-MALLS

:   size exclusion chromatography with multi-angle laser light scattering
